A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...
The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...
CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback